Wet AMD: Ranibizumab to Aflibercept Switch Does Not Improve Visual Acuity in Poor-Responders
AUGUST 11, 2016
In a poster session presented at the 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS 2016) in San Francisco, California, the team revealed outcomes with intravitreal aflibercept after patients did not respond to intravitreal ranibizumab well.
The participants, with an average age of nearly 70, had a mean follow-up of 33.8 months. On average, 2.2 aflibercept injections were given to the cohort after first trying about eight ranibizumab injections.
“Intravitreal aflibercept injections in wet AMD cases who were poor responder to previous ranibizumab treatment provide good anatomical success,” the authors concluded. “However any significant improvement in visual acuity was not gained after drug switching.”
BCVA (logMAR) scores averaged at 0.42 at baseline, 0.45 at the time of drug switching, and 0.46 at their last visit. CMT (µm) moved from 404 at baseline, 395.8 at drug switching, and 300.9 at their last visit.
Also on MD Magazine >>> More News from ASRS 2016 in San Francisco